X4 Pharma Halves Workforce in Second Round of 2025 Layoffs

X4 Pharmaceuticals has announced a 50% workforce reduction in September 2025 as part of a restructuring to conserve resources and focus on completing its phase 3 study in chronic neutropenia13.

This is the second round of layoffs at X4 in 2025, following a 30% reduction (43 employees) in February that also included the closure of its Vienna research campus and pausing of pre-clinical drug candidates32.

The layoffs are expected to save the company around $13 million annually15.

These operational changes come shortly after a $60 million private placement and the resignations of CEO Paula Ragan and CFO Adam Mostafa1.

Executive chairman Adam Craig will oversee clinical development, while John Volpone (company president) will add chief operating officer duties to supervise day-to-day operations1.

Key executives including the chief legal and compliance officer, chief operating officer, and chief commercial officer will also depart as part of the restructuring1.

The company aims to concentrate resources on the 4WARD phase 3 clinical trial and to drive further operational efficiencies1.

Sources:

1. https://globalgenes.org/raredaily/x4-pharmaceuticals-cuts-half-its-workforce-in-restructuring/

2. https://www.biospace.com/job-trends/x4-pharmaceuticals-stumbles-again-laying-off-30-of-workforce

3. https://firstwordpharma.com/story/6093341

5. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025